Q2 2026 Holdings
Filed 2026-08-14 | 47 holdings | $1.1B | 13F-HR | View on SEC ↗ · Holdings Table ↗
Sign in to see sub-manager breakdown
| Issuer | Class | CUSIP | Value ↓ | Shares | % Portfolio |
|---|---|---|---|---|---|
| Trevi Therapeutics Inc(TRVI) | Common | 89532M101 | $95.0M | 5,094,668 | 8.7% |
| Praxis Precision Medicines(PRAX) | Common | 74006W207 | $90.8M | 271,116 | 8.3% |
| Erasca Inc(ERAS) | Common | 29479A108 | $75.6M | 4,127,412 | 6.9% |
| Arrivent BioPharma Inc(AVBP) | Common | 04272N102 | $58.4M | 1,682,097 | 5.3% |
| Abivax SA(ABVX) | SPONSORED ADS | 00370M103 | $55.3M | 414,899 | 5.0% |
| Tango Therapeutics Inc(TNGX) | Common | 87583X109 | $43.1M | 1,379,769 | 3.9% |
| Corvus Pharmaceuticals Inc(CRVS) | Common | 221015100 | $41.9M | 2,805,816 | 3.8% |
| Bright Minds Biosciences Inc(DRUG) | Common | 10919W405 | $39.1M | 557,172 | 3.6% |
| Sinovac Biotech Ltd.(SVA) | SHS | P8696W104 | $38.2M | 5,903,000 | 3.5% |
| Tenax Therapeutics Inc(TENX) | Common | 88032L605 | $36.4M | 2,500,000 | 3.3% |
| Aclaris Therapeutics, Inc.(ACRS) | Common | 00461U105 | $35.4M | 6,694,637 | 3.2% |
| Dyne Therapeutics Inc(DYN) | Common | 26818M108 | $34.6M | 1,557,466 | 3.2% |
| Dianthus Therapeutics Inc(DNTH) | Common | 252828108 | $34.5M | 353,998 | 3.2% |
| Alto Neuroscience Inc(ANRO) | Common | 02157Q109 | $31.9M | 1,208,858 | 2.9% |
| DBV Technologies SA(DBVT) | SPONSORED ADS | 23306J309 | $30.3M | 1,844,758 | 2.8% |
| SAB Biotherapeutics Inc(SABS) | Common | 78397T202 | $28.5M | 7,299,909 | 2.6% |
| Moonlake Immunotherapeutics(MLTX) | Class A ORD | 61559X104 | $27.3M | 1,400,000 | 2.5% |
| LB Pharmaceuticals Inc(LBRX) | Common | 50180M108 | $26.0M | 800,000 | 2.4% |
| Minerva Neurosciences Inc(NERV) | Common | 603380205 | $24.0M | 4,322,747 | 2.2% |
| Design Therapeutics Inc(DSGN) | Common | 25056L103 | $23.3M | 1,612,903 | 2.1% |
| Oric Pharmaceuticals Inc(ORIC) | Common | 68622P109 | $20.0M | 1,848,786 | 1.8% |
| Camp4 Therapeutics Corporation(CAMP) | Common | 13463J101 | $18.6M | 4,246,568 | 1.7% |
| Faeth Therapeutics Inc(SNSE) | Common | 81728A207 | $18.1M | 722,020 | 1.6% |
| Achieve Life Sciences Inc.(ACHV) | Common | 004468500 | $18.0M | 2,751,032 | 1.6% |
| Compass Therapeutics Inc(CMPX) | Common | 20454B104 | $17.0M | 7,757,060 | 1.6% |
| An2 Therapeutics Inc(ANTX) | Common | 037326105 | $15.3M | 3,153,640 | 1.4% |
| Editas Medicine Inc(EDIT) | Common | 28106W103 | $11.5M | 3,555,250 | 1.1% |
| Geron Corp(GERN) | Common | 374163103 | $11.1M | 8,671,797 | 1.0% |
| Odyssey Therapeutics Inc(ODTX) | Common | 67613T104 | $10.8M | 575,000 | 1.0% |
| Eupraxia Pharmaceuticals Inc(EPRX) | Common | 29842P105 | $8.9M | 1,350,000 | 0.8% |
| Onkure Therapeutics Inc(OKUR) | Common | 68277Q105 | $8.8M | 1,927,710 | 0.8% |
| Olema Pharmaceuticals Inc(OLMA) | Common | 68062P106 | $8.4M | 671,843 | 0.8% |
| Monopar Therapeutics Inc(MNPR) | Common | 61023L207 | $8.4M | 90,500 | 0.8% |
| Aura Biosciences Inc(AURA) | Common | 05153U107 | $8.3M | 1,166,667 | 0.8% |
| Surrozen Inc(SRZN) | Common | 86889P208 | $6.7M | 260,000 | 0.6% |
| ALX Oncology Holdings Inc(ALXO) | Common | 00166B105 | $6.6M | 3,184,713 | 0.6% |
| Satellos Bioscience Inc(MSLE) | Common | 80401L803 | $6.3M | 813,666 | 0.6% |
| Avalo Therapeutics Inc(AVTX) | Common | 05338F306 | $5.1M | 275,000 | 0.5% |
| Pepgen Inc(PEPG) | Common | 713317105 | $4.2M | 2,325,000 | 0.4% |
| Valneva SE(VALN) | SPONSORED ADS | 92025Y103 | $4.0M | 763,199 | 0.4% |
| Sera Prognostics Inc(SERA) | Common | 81749D107 | $3.0M | 1,650,440 | 0.3% |
| Unicycive Therapeutics(UNCY) | Common | 90466Y202 | $2.6M | 550,000 | 0.2% |
| Instil Bio Inc(TIL) | Common | 45783C200 | $2.3M | 292,743 | 0.2% |
| InMed Pharmaceuticals Inc(INM) | Common | 457637700 | $1.2M | 798,377 | 0.1% |
| Bolt Biotherapeutics Inc(BOLT) | Common | 097702203 | $278.8K | 72,414 | 0.0% |
| Pasithea Therapeutics Corp(KTTA) | Common | 70261F202 | $239.9K | 465,471 | 0.0% |
| Precision Biosciences Inc(DTIL) | Common | 74019P207 | $36.7K | 4,675 | 0.0% |